Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 8/20 | 0.42 |
| ▸ | AVPR1B | P47901 | 8/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.40 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590186 | 0.97 | OXTR (0.44) | OXTRAVPR1BAVPR1AAVPR2GPR65 | |
| SCHEMBL4589526 | 0.95 | OXTR (0.41) | OXTRAVPR1BAVPR1AAVPR2GPR65 | |
| SCHEMBL4590060 | 0.92 | OXTR (0.43) | OXTRAVPR1BAVPR1AAVPR2GPR65 | |
| SCHEMBL4590130 | 0.92 | OXTR (0.43) | OXTRAVPR1BAVPR1AAVPR2GPR65 | |
| SCHEMBL7162897 | 0.92 | OXTR (0.43) | OXTRAVPR1BAVPR1AAVPR2GPR65 | |
| SCHEMBL4588934 | 0.91 | OXTR (0.39) | OXTRAVPR1BAVPR1AAVPR2GPR65 | |
| SCHEMBL2496335 | 0.90 | AVPR1B (0.48) | OXTRAVPR1BAVPR1AAVPR2GPR65 | |
| SCHEMBL4588792 | 0.90 | CASP3 (0.38) | OXTRAVPR1BAVPR1AAVPR2BRD4 | |
| SCHEMBL2495591 | 0.88 | OXTR (0.50) | OXTRAVPR1BAVPR1AAVPR2GPR65 | |
| SCHEMBL4590303 | 0.88 | OXTR (0.43) | OXTRAVPR1BAVPR1AAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425566-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2008-09-16 | — | — | US | disclosed |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| US-6864277-B2 | 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-08 | — | — | US | disclosed |
| EP-1296976-B1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI AVENTIS (FR) | 2005-01-26 | — | — | EP | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | AVPR1B, AVPR1A, AVPR2 | OXTR 12/4885AVPR1B 1/4885AVPR1A 2/4885 |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR1B, AVPR2, AVPR1A | OXTR 9/4885AVPR1B 1/4885AVPR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.